NCT00730288

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: * To describe the safety of one injection of ChimeriVax™ dengue tetravalent vaccine. * To describe the immune response against dengue before and after one injection of ChimeriVax™ dengue tetravalent vaccine

Detailed description

This study will evaluate a dengue tetravalent vaccine formulation in subjects aged 18 to 40 years and previously immunised with a dengue or YF vaccine.

Conditions

• Dengue
• Dengue Fever
• Dengue Hemorrhagic Fever
• Dengue Virus

Interventions

Type	Name	Description
BIOLOGICAL	Chimeric dengue serotype (1, 2, 3, 4)	0.5 mL, Subcutaneous, 1 dose
BIOLOGICAL	Chimeric dengue serotype (1, 2, 3, 4)	0.5 mL, Subcutaneous, 1 dose
BIOLOGICAL	Chimeric dengue serotype (1, 2, 3, 4)	0.5mL, Subcutaneous, 1 dose

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-08-01
• Completion: 2008-01-01
• First posted: 2008-08-08
• Last updated: 2018-02-27

Locations

1 site across 1 country: Australia